Onco Wiki / Droga

Cisplatin

Visão determinística da entidade fonte YAML. A autoridade clínica permanece com os IDs de fonte citados e estado de assinatura do revisor.

IDDRUG-CISPLATIN
TipoFármaco
Alegais
CDDPAçúcarAQ Platinolcis-DDPЦисплатин
Estadoreviewed 2026-04-26 | pending_clinical_signoff
DoençasDIS-ADRENOCORTICAL-CARCINOMA DIS-BURKITT DIS-CERVICAL DIS-CHOLANGIOCARCINOMA DIS-ESOPHAGEAL DIS-GASTRIC DIS-HNSCC DIS-LARYNGEAL DIS-MCL DIS-MESOTHELIOMA DIS-NPC DIS-NSCLC DIS-PENILE-SCC DIS-SCLC DIS-TESTICULAR-GCT DIS-UROTHELIAL DIS-VULVAR-VAGINAL-SCC
FontesSRC-ESMO-ESOPHAGEAL-2024 SRC-NCCN-ESOPHAGEAL-2025

Fatos sobre as drogas

ClasseAgente alquilante de platina (primeira geração)
MecanismoSquare-planar platinum(II) coordination complex. After cellular uptake and aquation (Cl displaced by water in low-chloride intracellular environment), the activated species forms intra- and inter-strand DNA cross-links, predominantly 1,2-d(GpG) and 1,2-d(ApG) adducts. These adducts distort the DNA helix, blocking replication and transcription, and trigger apoptosis when not repaired. Resistance mechanisms include enhanced nucleotide excision repair, glutathione detoxification, and reduced cellular uptake (CTR1 transporter). Backbone for esophageal CRT, head-and-neck CRT, NSCLC, gastric (legacy), cervical, ovarian, testicular germ-cell, and bladder.
Dose típicaEsophageal definitive CRT (cisplatin/5-FU): cisplatin 75 mg/m² IV days 1, 29 + 5-FU 1000 mg/m²/d CIV days 1-4 and 29-32. Head-and-neck CRT: 100 mg/m² IV q21d × 3 cycles (high-dose) or 40 mg/m² weekly with RT. NSCLC (cisplatin/etoposide CRT): 50 mg/m² IV days 1, 8, 29, 36. NSCLC adjuvant (cisplatin/vinorelbine): 80 mg/m² IV day 1 q21d × 4. Testicular BEP: 20 mg/m² IV days 1-5 every 21 d × 3-4 cycles. Cervical CRT: 40 mg/m² IV weekly with RT (typically 5-6 cycles). Gastric (legacy ECF/EOX): 60-80 mg/m² IV q21d (FLOT preferred now). Mandatory hydration: ≥1-2 L NS pre-dose + 1-2 L post; mannitol diuresis or furosemide for high-dose schedules; Mg + K replacement.
Ucrânia registadaVerdade
NSZU reembolsadoVerdade
Ucrânia verificada pela última vez2026-04-27

Avisos

Notas

Mandatory hydration ≥3 L pre-dose + 24 h post; Mg / K pre-emptive supplementation. Consider carboplatin substitution for CrCl 50-60 or pre-existing hearing loss. Highly-emetogenic chemotherapy (HEC): ondansetron + dexamethasone + NK1-RA (aprepitant or fosaprepitant) + olanzapine premedication required (NCCN antiemesis v1.2025). Baseline + serial audiometry (esp. pediatric / younger adult patients). Uridine triacetate is NOT an antidote (FU only).

Usado por

Indicação

Esquema terapêutico